Laurence Chu

1.7k total citations · 1 hit paper
22 papers, 656 citations indexed

About

Laurence Chu is a scholar working on Epidemiology, Infectious Diseases and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Laurence Chu has authored 22 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 9 papers in Infectious Diseases and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Laurence Chu's work include Influenza Virus Research Studies (8 papers), Respiratory viral infections research (8 papers) and Viral gastroenteritis research and epidemiology (4 papers). Laurence Chu is often cited by papers focused on Influenza Virus Research Studies (8 papers), Respiratory viral infections research (8 papers) and Viral gastroenteritis research and epidemiology (4 papers). Laurence Chu collaborates with scholars based in United States, Belgium and Switzerland. Laurence Chu's co-authors include Brett Leav, Rolando Pajón, Hamilton Bennett, Biliana Nestorova, Wenmei Huang, Roderick McPhee, Brandon Essink, Rituparna Das, Scott A. Halperin and Yamuna Devi Paila and has published in prestigious journals such as Nature Medicine, The Journal of Infectious Diseases and The Lancet Infectious Diseases.

In The Last Decade

Laurence Chu

21 papers receiving 645 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials

2023 97 citations Brandon Essink, Laurence Chu et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurence Chu United States	13	391	255	143	109	57	22	656
Thanunrat Thongmee Thailand	18	550 1.4×	278 1.1×	73 0.5×	65 0.6×	106 1.9×	54	836
Shannon Emery United States	9	418 1.1×	756 3.0×	100 0.7×	69 0.6×	39 0.7×	13	1.0k
Claire M. Midgley United States	13	522 1.3×	271 1.1×	169 1.2×	109 1.0×	41 0.7×	26	938
Doris Chibo Australia	17	461 1.2×	578 2.3×	57 0.4×	106 1.0×	68 1.2×	36	894
Timothy Burgess United States	17	327 0.8×	354 1.4×	90 0.6×	133 1.2×	43 0.8×	51	803
Ramona Trebbien Denmark	22	460 1.2×	795 3.1×	125 0.9×	103 0.9×	49 0.9×	66	1.1k
Volker Vetter Belgium	12	195 0.5×	204 0.8×	80 0.6×	91 0.8×	106 1.9×	24	523
Karoline Bragstad Norway	19	508 1.3×	649 2.5×	129 0.9×	107 1.0×	57 1.0×	51	1.0k
Brandon Essink United States	15	622 1.6×	397 1.6×	225 1.6×	158 1.4×	119 2.1×	37	1.1k
Chakrarat Pittayawonganon Thailand	8	427 1.1×	732 2.9×	98 0.7×	120 1.1×	22 0.4×	18	898

Countries citing papers authored by Laurence Chu

Since Specialization

Citations

This map shows the geographic impact of Laurence Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Chu more than expected).

Fields of papers citing papers by Laurence Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Chu. The network helps show where Laurence Chu may publish in the future.

Co-authorship network of co-authors of Laurence Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Chu. A scholar is included among the top collaborators of Laurence Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Chu. Laurence Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bennett, Chijioke, Gordon Chau, Elizabeth Clayton, et al.. (2025). Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial. Journal of Infection. 90(2). 106428–106428.

Chu, Laurence, et al.. (2024). Functional excitation-inhibition ratio for social anxiety analysis and severity assessment. Frontiers in Psychiatry. 15. 1461290–1461290. 1 indexed citations

Essink, Brandon, Laurence Chu, Elizabeth Barranco, et al.. (2023). The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. The Lancet Infectious Diseases. 23(5). 621–633. 97 indexed citations breakdown →

Chu, Laurence, Keith Vrbicky, David C. Montefiori, et al.. (2022). Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine. 28(5). 1042–1049. 56 indexed citations

Pichon, Sylvie, Annick Moureau, Céline Petit, et al.. (2022). Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study. Vaccine. 40(33). 4780–4787. 8 indexed citations

Folschweiller, Nicolas, Carline Vanden Abeele, Laurence Chu, et al.. (2022). Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial. The Lancet Infectious Diseases. 22(7). 1062–1075. 17 indexed citations

August, Allison, Christine A. Shaw, Heather Lee, et al.. (2022). Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults. Open Forum Infectious Diseases. 9(7). ofac206–ofac206. 50 indexed citations

Chu, Laurence, Roderick McPhee, Wenmei Huang, et al.. (2021). A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 39(20). 2791–2799. 146 indexed citations

Standaert, Baudouin, Stephan Bart, Laurence Chu, et al.. (2019). Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study. Health and Quality of Life Outcomes. 17(1). 80–80. 8 indexed citations

10.

Frenck, Robert W., John Ervin, Laurence Chu, et al.. (2019). Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. The Lancet Infectious Diseases. 19(6). 631–640. 57 indexed citations

11.

Suriyaarachchi, Pushpa, et al.. (2019). Evaluating Effectiveness of an Acute Rehabilitation Program in Hospital-Associated Deconditioning. Journal of Geriatric Physical Therapy. 43(4). 172–178. 10 indexed citations

12.

Atmar, Robert L., Frank Baehner, Jakob P. Cramer, et al.. (2019). Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. The Journal of Infectious Diseases. 220(4). 603–614. 22 indexed citations

13.

Beran, Jiřı́, Jason D. Lickliter, Tino F. Schwarz, et al.. (2018). Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials. The Journal of Infectious Diseases. 217(10). 1616–1625. 35 indexed citations

14.

Sheldon, Eric, Louise Frenette, Laurence Chu, et al.. (2017). Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial. Vaccine. 35(35). 4621–4628. 12 indexed citations

15.

Ferguson, Murdo, Eric Sheldon, Nathan Segall, et al.. (2017). Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial. Vaccine. 35(10). 1431–1439. 10 indexed citations

16.

Treanor, John J., Laurence Chu, Brandon Essink, et al.. (2017). Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 35(6). 923–928. 9 indexed citations

17.

Halperin, Scott A., José Ramón Arribas, Richard Rupp, et al.. (2017). Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. The Journal of Infectious Diseases. 215(12). 1789–1798. 56 indexed citations

18.

Jain, Varsha, Joseph B. Domachowske, Long Wang, et al.. (2016). Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial. Journal of the Pediatric Infectious Diseases Society. 6(1). piw068–piw068. 22 indexed citations

19.

Langley, Joanne M., Louise Frenette, Robert Jeanfreau, et al.. (2014). Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial. Vaccine. 33(4). 559–567. 16 indexed citations

20.

Langley, Joanne M., Louise Frenette, Laurence Chu, et al.. (2012). A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infectious Diseases. 12(1). 279–279. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact